| Identification | Back Directory | [Name]
3,3′-[6,6′-bi-1H-Benzimidazole]-2,2′-diylbis-benzenamine | [CAS]
4402-18-0 | [Synonyms]
DDRI-18
DDRI18,DDRI 18
3,3′-[6,6′-bi-1H-Benzimidazole]-2,2′-diylbis-benzenamine
Benzenamine, 3,3'-[6,6'-bi-1H-benzimidazole]-2,2'-diylbis- | [Molecular Formula]
C26H20N6 | [MDL Number]
MFCD01137750 | [MOL File]
4402-18-0.mol | [Molecular Weight]
416.48 |
| Chemical Properties | Back Directory | [Melting point ]
297-299 °C | [Boiling point ]
835.8±75.0 °C(Predicted) | [density ]
1.382±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble10mg/mL | [form ]
powder | [pka]
10.77±0.10(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
DDRI-18 is a DNA damage response inhibitor that inhibits the non-homologous end-joining (NHEJ) DNA repair process. DDRI-18 is an effective chemosensitizing agent[1]. | [Biochem/physiol Actions]
DDRI-18 (DNA Damage Response Inhibitor-18) inhibits nonhomologous end-joining (NHEJ) DNA repair following double strand DNA breaks induced by ionizing radiation, and enhances the effects of DNA-damaging cancer drugs like etoposide, camptothecin and doxorubicin. | [References]
[1] D W Jun, et al. Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response. Br J Pharmacol. 2012 Sep;167(1):141-50. DOI:10.1111/j.1476-5381.2012.01977.x |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|